.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Healthtrust
Cipla
QuintilesIMS
Johnson and Johnson
Citi
Mallinckrodt
Federal Trade Commission
Moodys
Colorcon

Generated: November 21, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,932,241

« Back to Dashboard

Which drugs does patent 7,932,241 protect, and when does it expire?


Patent 7,932,241 protects ZOMETA and RECLAST and is included in two NDAs. There have been zero Paragraph IV challenges on Zometa and Reclast

Protection for RECLAST has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-six patent family members in twenty-two countries.

Summary for Patent: 7,932,241

Title:Pharmaceutical products comprising bisphosphonates
Abstract: A pharmaceutical product comprises a container containing a bisphosphonate solution, in which at least the internal surface of the container comprises a plastic material and in which the container is heat sterilisable, and which is in the form of a ready to use infusion solution, for administration of the bisphosphonate to a patient in need of bisphosphonate treatment.
Inventor(s): Glausch; Alexandra (Weil am Rhein, DE), Loffler; Rolf (Freiburg, DE), Sigg; Juergen (Loerrach, DE)
Assignee: Novartis AG (Basel, CH)
Application Number:10/570,339
Patent Claim Types:
see list of patent claims
Formulation; Compound; Process;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novartis
ZOMETA
zoledronic acid
INJECTABLE;IV (INFUSION)021223-003Jun 17, 2011APRXYesYes► Subscribe► SubscribeY
Novartis
RECLAST
zoledronic acid
INJECTABLE;IV (INFUSION)021817-001Apr 16, 2007APRXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,932,241

PCT Information
PCT FiledSeptember 17, 2004PCT Application Number:PCT/EP2004/010470
PCT Publication Date:March 24, 2005PCT Publication Number: WO2005/025551

International Patent Family for Patent: 7,932,241

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Peru04682005► Subscribe
New Zealand545343► Subscribe
Norway20061682► Subscribe
Malaysia141763► Subscribe
Morocco28078► Subscribe
South Korea101015718► Subscribe
South Korea20060087568► Subscribe
Japan4802096► Subscribe
Iceland8351► Subscribe
Japan2007505861► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Novartis
Queensland Health
Julphar
Johnson and Johnson
Merck
Mallinckrodt
Harvard Business School
Medtronic
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot